Literature DB >> 15569669

Molecular ordering of the caspase activation cascade initiated by the cytotoxic T lymphocyte/natural killer (CTL/NK) protease granzyme B.

Colin Adrain1, Brona M Murphy, Seamus J Martin.   

Abstract

Granzyme B is a major cytotoxic T lymphocyte/natural killer (CTL/NK) granule protease that can activate members of the caspase family of cysteine proteases through processing of caspase zymogens. However, the molecular order and relative importance of caspase activation events that occur in target cells during granzyme B-initiated apoptosis has not been established. Here, we have examined the hierarchy of granzyme B-initiated caspase activation events using a cell-free system where all caspases are present at physiological levels. We show that granzyme B initiates a two-tiered caspase activation cascade involving seven caspases, where caspase-3 is required for the second tier of caspase activation events. Using a two-dimensional gel-based proteomics approach we have also examined the scale of granzyme B-initiated alterations to the proteome in the presence or absence of effector caspase-3 or -7. These studies indicate that granzyme B targets a highly restricted range of substrates and orchestrates cellular demolition largely through activation of caspase-3.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15569669     DOI: 10.1074/jbc.M410915200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  40 in total

1.  Cytotoxic T lymphocyte perforin and Fas ligand working in concert even when Fas ligand lytic action is still not detectable.

Authors:  David Hassin; Orit G Garber; Avihai Meiraz; Yael S Schiffenbauer; Gideon Berke
Journal:  Immunology       Date:  2011-03-29       Impact factor: 7.397

Review 2.  A quarter century of granzymes.

Authors:  C L Ewen; K P Kane; R C Bleackley
Journal:  Cell Death Differ       Date:  2011-11-04       Impact factor: 15.828

3.  Probing the efficiency of proteolytic events by positional proteomics.

Authors:  Kim Plasman; Petra Van Damme; Dion Kaiserman; Francis Impens; Kimberly Demeyer; Kenny Helsens; Marc Goethals; Phillip I Bird; Joël Vandekerckhove; Kris Gevaert
Journal:  Mol Cell Proteomics       Date:  2010-11-03       Impact factor: 5.911

4.  Mesenchymal stem cells express serine protease inhibitor to evade the host immune response.

Authors:  Najib El Haddad; Dean Heathcote; Robert Moore; Sunmi Yang; Jamil Azzi; Bechara Mfarrej; Mark Atkinson; Mohamed H Sayegh; Jeng-Shin Lee; Philip G Ashton-Rickardt; Reza Abdi
Journal:  Blood       Date:  2010-11-12       Impact factor: 22.113

5.  The major human and mouse granzymes are structurally and functionally divergent.

Authors:  Dion Kaiserman; Catherina H Bird; Jiuru Sun; Antony Matthews; Kheng Ung; James C Whisstock; Philip E Thompson; Joseph A Trapani; Phillip I Bird
Journal:  J Cell Biol       Date:  2006-11-20       Impact factor: 10.539

Review 6.  Use of protease proteomics to discover granzyme B substrates.

Authors:  Andrew J Bredemeyer; R Reid Townsend; Timothy J Ley
Journal:  Immunol Res       Date:  2005       Impact factor: 2.829

Review 7.  Death by a thousand cuts: granzyme pathways of programmed cell death.

Authors:  Dipanjan Chowdhury; Judy Lieberman
Journal:  Annu Rev Immunol       Date:  2008       Impact factor: 28.527

8.  Identification of Serpinb6b as a species-specific mouse granzyme A inhibitor suggests functional divergence between human and mouse granzyme A.

Authors:  Dion Kaiserman; Sarah E Stewart; Kim Plasman; Kris Gevaert; Petra Van Damme; Phillip I Bird
Journal:  J Biol Chem       Date:  2014-02-06       Impact factor: 5.157

Review 9.  Granzyme B cleavage of autoantigens in autoimmunity.

Authors:  E Darrah; A Rosen
Journal:  Cell Death Differ       Date:  2010-01-15       Impact factor: 15.828

10.  Bicaudal is a conserved substrate for Drosophila and mammalian caspases and is essential for cell survival.

Authors:  Emma M Creagh; Gabriela Brumatti; Clare Sheridan; Patrick J Duriez; Rebecca C Taylor; Sean P Cullen; Colin Adrain; Seamus J Martin
Journal:  PLoS One       Date:  2009-03-30       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.